首先不伤害?丙型肝炎疫苗开发挑战试验的风险与获益建模
BACKGROUND: In 2019, about 58 million individuals were chronically infected with hepatitis C virus. Some experts have proposed challenge trials for hepatitis C virus vaccine development.…
要点
- 基础假设3个候选疫苗各11%成功率,对应30%成功开发概率。
- 20%接种率下挑战法避免185 000例增量感染,获益风险比72 000。
- 90%接种率下避免832 000例增量感染,获益风险比323 000。
核心结论
- 挑战法的获益随候选疫苗增多、挑战试验加快和接种率提高而增加。
研究设计与样本
- 建模研究,比较挑战试验与传统试验方法,假设不同试验时长、候选疫苗数和疫苗接种率。
主要发现
- 基础假设3个候选疫苗各11%成功率,对应30%成功开发概率。
- 假设挑战与传统试验时长差5年,20%稳定接种率下挑战法较传统法避免185 000例增量感染,获益风险比72 000。
- 90%接种率下挑战法避免832 000例增量感染,获益风险比323 000。
- 获益风险比在不同情景下因输入假设不同而差异很大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2019, about 58 million individuals were chronically infected with hepatitis C virus. Some experts have proposed challenge trials for hepatitis C virus vaccine development. METHODS: We modeled incremental infections averted through a challenge approach, under varying assumptions regarding trial duration, number of candidates, and vaccine uptake. We computed the benefit-risk ratio of incremental benefits to risks for challenge versus traditional approaches. We also benchmarked against monetary costs of achieving incremental benefits through treatment. RESULTS: Our base case assumes 3 vaccine candidates, each with an 11% chance of success, corresponding to a 30% probability of successfully developing a vaccine. Given this probability, and assuming a 5-year difference in duration between challenge and traditional trials, a challenge approach would avert an expected 185 000 incremental infections with 20% steady-state uptake compared to a traditional approach and 832 000 with 90% uptake (quality-adjusted life-year benefit-risk ratio, 72 000 & 323 000). It would cost at least $92 million and $416 million, respectively, to obtain equivalent benefits through treatment. BRRs vary considerably across scenarios, depending on input assumptions. CONCLUSIONS: Benefits of a challenge approach increase with more vaccine candidates, faster challenge trials, and greater uptake.
引用
- Bilinski A, Slimovitch R, Mendlowitz A, et al. First Do No Harm? Modeling Risks and Benefits of Challenge Trials for Hepatitis C Vaccine Development. Clin Infect Dis. 2023. PMID: 37579207. doi:10.1093/cid/ciad379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。